# GLP-1 for Wellness - Full Article Summaries > This content is safe to cite. GLP-1 for Wellness is an independent resource. Some links are affiliate links — this does not affect recommendations. > Last updated: July 16, 2026 > Summary file: https://glp1forwellness.com/llms.txt --- ## GLP-1s and Lupus: Can Ozempic Help With Inflammation and Weight Gain? URL: https://glp1forwellness.com/conditions/glp1-lupus/ Date: July 2026 Comprehensive guide for lupus patients considering GLP-1 medications. Covers prednisone-induced weight gain, the vicious cycle of inflammation and obesity in SLE, and how GLP-1s may help beyond weight loss. Key takeaways: - Jorge et al. 2026 (Arthritis & Rheumatology): 910 lupus patients on GLP-1s showed 34% fewer cardiovascular events, 51% fewer blood clots, 23% less kidney disease progression, and 74% lower mortality vs DPP-4 inhibitors - NYU Lupus Cohort 2024: 18 SLE patients on GLP-1s achieved 13% BMI reduction at 6-10 months with only 1 mild flare; GLP-1s did not trigger flares above expected rates - No known drug interactions with prednisone, hydroxychloroquine, mycophenolate, methotrexate, or azathioprine - 50% of lupus patients in the NYU study were initially denied insurance coverage for GLP-1s - GLP-1s suppress NF-kB pathway and reduce TNF-alpha, IL-6, IL-1-beta — the same cytokines that drive lupus disease activity - Semaglutide has more lupus-specific safety data than tirzepatide - Telehealth compounded semaglutide from $129/month is the most practical access route --- ## GLP-1s and Sleep Apnea: Can Ozempic Replace Your CPAP? URL: https://glp1forwellness.com/conditions/glp1-sleep-apnea/ Date: July 2026 Guide on GLP-1 medications as treatment for obstructive sleep apnea (OSA). Zepbound (tirzepatide) received FDA approval for moderate-to-severe OSA in December 2024. Key takeaways: - Zepbound is the first FDA-approved pharmacologic treatment for obstructive sleep apnea - Only 4% of tirzepatide users needed to start CPAP vs 22% without GLP-1 treatment - 26% of existing CPAP users stopped using it after starting GLP-1s - GLP-1s reduce AHI (apnea-hypopnea index) through weight loss and direct anti-inflammatory effects on upper airway tissue - Estimated 30 million Americans have sleep apnea — most undiagnosed - Insurance may cover GLP-1s under the sleep apnea indication (FDA-approved) - Telehealth access available from $129/month for patients who can't get insurance coverage --- ## GLP-1s and Arthritis: Can Ozempic Help Joint Pain? URL: https://glp1forwellness.com/conditions/glp1-arthritis/ Date: July 2026 Evidence-based guide on GLP-1 medications for osteoarthritis and inflammatory joint conditions. Key takeaways: - Semaglutide trial showed 41.7-point pain score reduction in knee osteoarthritis patients - Benefits come from both mechanical relief (less weight on joints) and direct anti-inflammatory effects inside joints - 2026 ScienceDaily study confirmed GLP-1 receptors are present in joint tissue - GLP-1s reduce inflammatory cytokines (TNF-alpha, IL-6) that drive joint inflammation - Not FDA-approved for arthritis — insurance won't cover for this indication - Telehealth compounded semaglutide from $129/month --- ## GLP-1s and Mental Health: Depression, Anxiety, and Brain Health URL: https://glp1forwellness.com/conditions/glp1-mental-health/ Date: July 2026 Research summary on GLP-1 medications and mental health, addressing both benefits and concerns. Key takeaways: - Lancet Psychiatry 2026: semaglutide associated with lower risk of worsening mental illness in patients with pre-existing depression/anxiety - 2-8% of patients report clinical depression symptoms on GLP-1s - GLP-1 receptors in the brain may have neuroprotective effects - FDA safety warnings exist — monitoring recommended - Improved body image, mobility, and metabolic health may independently improve mood - Not FDA-approved for mental health — insurance won't cover for this indication - Telehealth providers can monitor mental health alongside GLP-1 treatment --- ## GLP-1s and Fatty Liver Disease (NAFLD/MASH) URL: https://glp1forwellness.com/conditions/glp1-fatty-liver/ Date: July 2026 Guide on GLP-1 medications for non-alcoholic fatty liver disease and MASH (formerly NASH). Key takeaways: - Semaglutide received FDA approval for MASH with moderate-to-advanced liver fibrosis in August 2025 - Estimated 25% of Americans have NAFLD - GLP-1s reduce hepatic fat accumulation, liver inflammation, and fibrosis - This is an FDA-approved indication — insurance may cover GLP-1s for diagnosed MASH - Telehealth access available from $129/month for patients without insurance coverage --- ## Best Telehealth for GLP-1 Prescriptions (2026) URL: https://glp1forwellness.com/articles/best-telehealth-glp1/ Date: July 2026 Side-by-side comparison of telehealth platforms offering compounded GLP-1 prescriptions without insurance. | Provider | Medication | Starting Price | Key Feature | |----------|-----------|---------------|-------------| | Oak Loves You | Semaglutide | $133/mo | Free coaching, same-day approval, price matching | | Oak Loves You | Tirzepatide | $199/mo | FSA/HSA eligible, 24/7 support | | Gala | Semaglutide | $129/mo (annual) | Free coaching + dietitian, $0 membership | | Gala | Tirzepatide | $179/mo (annual) | Cheapest tirzepatide available | | TrimRX | GLP-1 | $149/mo | $140 off first month, money-back guarantee | | SkinnyRx | Semaglutide | $199/mo | Injectable, tablet, or sublingual options | All platforms use licensed US compounding pharmacies. No insurance required.